NEW YORK ( TheStreet) -- Human Genome Sciences Inc (Nasdaq: HGSI) hit a new 52-week low Monday as it is currently trading at $11.04, below its previous 52-week low of $11.05 with 3.1 million shares traded as of 12:56 p.m. ET. Average volume has been 4.6 million shares over the past 30 days. Human Genome Sciences has a market cap of $2.4 billion and is part of the health care sector and drugs industry. Shares are down 46.6% year to date as of the close of trading on Friday. Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax.
- Practice your HGSI trading strategies and win cash in our stock game.